Supplemental Materials: Pharmacokinetics and pharmacodynamics of clofazimine for treatment of cryptosporidiosis

Cindy X. Zhang\(^a\), Melissa S. Love\(^b\), Case W. McNamara\(^b\), Victor Chi\(^b\), Ashley K. Woods\(^b\), Sean Joseph\(^b\), Deborah A. Schaefer\(^c\), Dana P. Betzer\(^c\), Michael W. Riggs\(^c\), Pui-Ying Iroh Tam\(^d,e\), Wesley C. Van Voorhis\(^i\), Samuel L.M. Arnold\(^a,f#\)

\(^a\)Department of Pharmaceutics, University of Washington, Seattle, Washington, USA
\(^b\)Calibr, a division of The Scripps Research Institute, La Jolla, California, USA
\(^c\)School of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, Arizona, USA
\(^d\)Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
\(^e\)Liverpool School of Tropical Medicine, Liverpool, UK.
\(^f\)Department of Medicine, University of Washington, Seattle, Washington, USA

Running Head: Clofazimine pharmacokinetics and pharmacodynamics

#Address correspondence to Samuel L. M. Arnold, slarnold@uw.edu.

**Keywords:** Cryptosporidiosis, pharmacokinetics, pharmacodynamics, PK/PD, gastrointestinal, infectious diseases
Supplemental Figure 1: Calf PD outcomes vs. clofazimine Cavg

- **Fecal Volume AUC24−192 vs. Clofazimine Cavg 0−192**
  - Scatter plot showing the relationship between fecal volume and clofazimine concentration.

- **Fecal Consistency Score AUC24−192 vs. Clofazimine Cavg 0−192**
  - Scatter plot showing the relationship between fecal consistency score and clofazimine concentration.

- **Clinical Score AUC24−192 vs. Clofazimine Cavg 0−192**
  - Scatter plot showing the relationship between clinical score and clofazimine concentration.

- **Urine Volume AUC24−192 vs. Clofazimine Cavg 0−192**
  - Scatter plot showing the relationship between urine volume and clofazimine concentration.
Supplemental Figure 2: Clinical Trial: rate of reduction vs. CFZ Cavg 96-108.